GBIM Stock Overview
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
GlobeImmune, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.0008 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -99.88% |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
GBIM | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -5.0% | -3.5% |
1Y | -99.9% | -1.7% | 20.2% |
Return vs Industry: GBIM underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: GBIM underperformed the US Market which returned 20.2% over the past year.
Price Volatility
GBIM volatility | |
---|---|
GBIM Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GBIM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine GBIM's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | n/a | n/a | www.globeimmune.com |
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.
GlobeImmune, Inc. Fundamentals Summary
GBIM fundamental statistics | |
---|---|
Market cap | US$5.00 |
Earnings (TTM) | -US$2.07m |
Revenue (TTM) | US$6.21m |
0.0x
P/S Ratio0.0x
P/E RatioIs GBIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GBIM income statement (TTM) | |
---|---|
Revenue | US$6.21m |
Cost of Revenue | US$2.08m |
Gross Profit | US$4.13m |
Other Expenses | US$6.20m |
Earnings | -US$2.07m |
Last Reported Earnings
Mar 31, 2016
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did GBIM perform over the long term?
See historical performance and comparison